This is a continuation of pre-ASCO coverage, reviewing companies that will have significant clinical presentations on cancer products in their pipeline.
Incyte Corporation (INCY $17.82) up 1.94%. is focused on small molecule drugs for hematological and oncology applications and for chronic autoimmune and inflammatory diseases.In oncology the Company has four indications for its JAK inhibitor ruxolitinab. Data presentations on the COMFORT-I and COMFORT-II studies will be made at ASCO on June 6.
Onyx Pharmaceuticals Inc. (ONXX $42.65) up 0.97%, has a broad pipeline of products for cancers: liver, kidney, NSCLC,thyroid, ovarian,colorectal and breast. Several studies will be presented at ASCO on carfilzomib, a selective next- generation proteazome inhibitor for multiple myeloma.
Supergen (SUPG $3.19) up 0.95%, will present at ASCO on June 6 ,Phase III data of decitabine (Dacogen) for treatment of older pateints with AML, in collaboration with JNJ and Eisai. Favorable results could increase the royalty stream for Dacogen.